The novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions

Behavioural Brain Research

Volumn 223, Issue 2, 2011, Pages 271-279

  Saitoh, Akiyoshi ^a,b   Sugiyama, Azusa ^a,b   Nemoto, Toru ^c   Fujii, Hideaki ^c   Wada, Keiji ^d   Oka, Jun Ichiro ^b   Nagase, Hiroshi ^c   Yamada, Mitsuhiko ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Analgesics; Antidepressants; Forced swim test; Formalin test; Opioid delta subtype; Writhing test

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; 7 BENZYLIDENENALTREXONE; ACETIC ACID; DELTA OPIATE RECEPTOR AGONIST; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; IMIPRAMINE; KNT 127; NALTRIBEN; NALTRINDOLE; UNCLASSIFIED DRUG;

ABDOMEN; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG ACTIVITY; EXPERIMENTAL TEST; FORCED SWIMMING TEST; FORMALIN TEST; IMMOBILIZATION; LICKING; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WRITHING TEST;

ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; BENZAMIDES; DEPRESSION; DOPAMINE ANTAGONISTS; IMIPRAMINE; MALE; MICE; MICE, INBRED ICR; MORPHINANS; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PIPERAZINES; RECEPTORS, OPIOID, DELTA; SEIZURES; SWIMMING;

EID: 79959309365     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.04.041     Document Type: Article

References (63)

1. Le Merrer J., Becker J.A., Befort K., Kieffer B.L. Reward processing by the opioid system in the brain. Physiol Rev 2009, 89:1379-1412.
2. Madar I., Lever J.R., Kinter C.M., Scheffel U., Ravert H.T., Musachio J.L., et al. Imaging of delta opioid receptors in human brain by N1′-([11C]methyl)naltrindole and PET. Synapse 1996, 24:19-28.
3. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W., Simonin F., et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000, 25:195-200.
4. Broom D.C., Jutkiewicz E.M., Folk J.E., Traynor J.R., Rice K.C., Woods J.H. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 2002, 26:744-755.
5. Pradhan A.A., Walwyn W., Nozaki C., Filliol D., Erbs E., Matifas A., et al. Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci 2010, 30:16459-16468.
6. Saitoh A., Yoshikawa Y., Onodera K., Kamei J. Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl) 2005, 182:327-334.
7. Broom D.C., Jutkiewicz E.M., Rice K.C., Traynor J.R., Woods J.H. Behavioral effects of delta-opioid receptor agonists: potential antidepressants?. Jpn J Pharmacol 2002, 90:1-6.
8. Jutkiewicz E.M., Rice K.C., Woods J.H., Winsauer P.J. Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav Pharmacol 2003, 14:509-516.
9. Narita M., Funada M., Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 2001, 89:1-15.
10. Ossipov M., Lai J., Vanderah T., Porreca F. The delta opioid receptor subtypes and pain modulation. The delta receptor 2004, 297-329. Marcel Dekker, Inc., New York. K.J. Chang, F. Porreca, J.H. Woods (Eds.).
11. Saitoh A., Yamada M., Takahashi K., Yamaguchi K., Murasawa H., Nakatani A., et al. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res 2008, 1208:160-169.
12. Evans C.J., Keith D.E., Morrison H., Magendzo K., Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science 1992, 258:1952-1955.
13. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992, 89:12048-12052.
14. Mattia A., Vanderah T., Mosberg H.I., Porreca F. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther 1991, 258:583-587.
15. Suzuki T., Tsuji M., Mori T., Misawa M., Endoh T., Nagase H. Effects of a highly selective nonpeptide delta opioid receptor agonist, TAN-67, on morphine-induced antinociception in mice. Life Sci 1995, 57:155-168.
16. Zaki P.A., Bilsky E.J., Vanderah T.W., Lai J., Evans C.J., Porreca F. Opioid receptor types and subtypes: the delta receptor as a model. Annu Rev Pharmacol Toxicol 1996, 36:379-401.
17. Tseng L.F., Narita M., Mizoguchi H., Kawai K., Mizusuna A., Kamei J., et al. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord. J Pharmacol Exp Ther 1997, 280:600-605.
18. Narita M., Suzuki T. Delta opioid receptor-mediated antinociception/analgesia. The delta receptor 2004, 331-354. Marcel Dekker, Inc., New York. K.J. Chang, F. Porreca, J.H. Woods (Eds.).
19. Hutcheson D.M., Matthes H.W., Valjent E., Sánchez-Blázquez P., Rodríguez-Díaz M., Garzón J., et al. Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. Eur J Neurosci 2001, 13:153-161.
20. Scherrer G., Befort K., Contet C., Becker J., Matifas A., Kieffer B.L. The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice. Eur J Neurosci 2004, 19:2239-2248.
21. Alfaras-Melainis K., Gomes I., Rozenfeld R., Zachariou V., Devi L. Modulation of opioid receptor function by protein-protein interactions. Front Biosci 2009, 14:3594-3607.
22. Nagase H., Kawai K., Hayakawa J., Wakita H., Mizusuna A., Matsuura H., et al. Rational drug design and synthesis of a highly selective nonpeptide delta-opioid agonist, (4aS,12aR)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octahydropyrido[3,4-b]acridine (TAN-67). Chem Pharm Bull (Tokyo) 1998, 46:1695-1702.
23. Bilsky E.J., Calderon S.N., Wang T., Bernstein R.N., Davis P., Hruby V.J., et al. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther 1995, 273:359-366.
24. Chang K.J., Rigdon G.C., Howard J.L., McNutt R.W. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 1993, 267:852-857.
25. Kamei J., Saitoh A., Ohsawa M., Suzuki T., Misawa M., Nagase H., et al. Antinociceptive effects of the selective non-peptidic delta-opioid receptor agonist TAN-67 in diabetic mice. Eur J Pharmacol 1995, 276:131-135.
26. Broom D.C., Nitsche J.F., Pintar J.E., Rice K.C., Woods J.H., Traynor J.R. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 2002, 303:723-729.
27. Saitoh A., Kimura Y., Suzuki T., Kawai K., Nagase H., Kamei J. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 2004, 95:374-380.
28. Nagase H, Tanaka T, Saitoh A, inventor; Toray Industries Inc., assignee. Therapeutics of preventive medicines for mood disorders or anxiety disorders. WO/2002/002117; 2002 Oct 1.
29. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
30. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
31. Cordonnier L., Sanchez M., Roques B.P., Noble F. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 2005, 135:1-10.
32. Takahashi K., Saitoh A., Yamada M., Maruyama Y., Hirose N., Kamei J. Gene expression profiling reveals complex changes in the olfactory bulbectomy model of depression after chronic treatment with antidepressants. J Pharmacol Sci 2008, 108:320-334.
33. Comer S.D., Hoenicke E.M., Sable A.I., McNutt R.W., Chang K.J., De Costa B.R., et al. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 1993, 267:888-895.
34. Negus S.S., Butelman E.R., Chang K.J., DeCosta B., Winger G., Woods J.H. Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther 1994, 270:1025-1034.
35. Broom D.C., Jutkiewicz E.M., Folk J.E., Traynor J.R., Rice K.C., Woods J.H. Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) 2002, 164:42-48.
36. Jutkiewicz E.M., Eller E.B., Folk J.E., Rice K.C., Traynor J.R., Woods J.H. Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther 2004, 309:173-181.
37. Nagase H., Nemoto T., Matsubara A., Saito M., Yamamoto N., Osa Y., et al. Design and synthesis of KNT-127, a delta-opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett 2010, 20:6302-6305.
38. Nagase H., Osa Y., Nemoto T., Fujii H., Imai M., Nakamura T., et al. Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett 2009, 19:2792-2795.
39. Gaveriaux-Ruff C., Nozaki C., Nadal X., Hever X.C., Weibel R., Matifas A., et al. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 2011, (February). [Epub ahead of print].
40. Endoh T., Matsuura H., Tajima A., Izumimoto N., Tajima C., Suzuki T., et al. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci 1999, 65:1685-1694.
41. Hunskaar S., Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987, 30:103-114.
42. Kamei J., Kawai K., Mizusuna A., Saitoh A., Morita K., Narita M., et al. Supraspinal delta 1-opioid receptor-mediated antinociceptive properties of (-)-TAN-67 in diabetic mice. Eur J Pharmacol 1997, 322:27-30.
43. Petrillo P., Angelici O., Bingham S., Ficalora G., Garnier M., Zaratin P.F., et al. Evidence for a selective role of the delta-opioid agonist [8R-(4bS,8aalpha,8abeta,12bbeta)]7,10-dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses. J Pharmacol Exp Ther 2003, 307:1079-1089.
44. Le Bourdonnec B., Windh R.T., Ajello C.W., Leister L.K., Gu M., Chu G.H., et al. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859). J Med Chem 2008, 51:5893-5896.
45. Le Bourdonnec B., Windh R.T., Leister L.K., Zhou Q.J., Ajello C.W., Gu M., et al. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4′-piperidine]-4-yl) benzamide (ADL5747). J Med Chem 2009, 52:5685-5702.
46. Codd E.E., Carson J.R., Colburn R.W., Stone D.J., Van Besien C.R., Zhang S.P., et al. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. J Pharmacol Exp Ther 2009, 329:241-251.
47. Hudzik T.J., Maciag C., Smith M.A., Caccese R., Pietras M.R., Bui K.H., et al. Preclinical pharmacology of AZD2327 - a highly selective agonist of the d opioid receptor. J Pharmacol Exp Ther 2011, [Epub ahead of print].
48. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29:547-569.
49. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
50. Gavériaux-Ruff C., Karchewski L.A., Hever X., Matifas A., Kieffer B.L. Inflammatory pain is enhanced in delta opioid receptor-knockout mice. Eur J Neurosci 2008, 27:2558-2567.
51. Lever J.R., Stathis M., Kinter C.M., Scheffel U. In vivo labeling of delta opioid receptors in mouse brain by [3H]benzylidenenaltrexone, a ligand selective for the delta 1 subtype. Life Sci 1996, 58:PL331-PL336.
52. Lever J.R., Scheffel U. Selective in vivo binding of [3H]naltriben to delta-opioid receptors in mouse brain. Eur J Pharmacol 1998, 350:335-344.
53. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 1994, 45:330-334.
54. Allouche S., Hasbi A., Ferey V., Sola B., Jauzac P., Polastron J. Pharmacological delta1- and delta2-opioid receptor subtypes in the human neuroblastoma cell line SK-N-BE: no evidence for distinct molecular entities. Biochem Pharmacol 2000, 59:915-925.
55. Parkhill A.L., Bidlack J.M. Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor. Eur J Pharmacol 2002, 451:257-264.
56. Van Rijn R.M., Whistler J.L. The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry 2009, 66:777-784.
57. Gaveriaux-Ruff C., Peluso J., Befort K., Simonin F., Zilliox C., Kieffer B.L. Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid receptors. Brain Res Mol Brain Res 1997, 48:298-304.
58. Mayer P., Tischmeyer H., Jayasinghe M., Bonnekoh B., Gollnick H., Teschemacher H., et al. A delta opioid receptor lacking the third cytoplasmic loop is generated by atypical mRNA processing in human malignomas. FEBS Lett 2000, 480:156-160.
59. Matthes H.W., Smadja C., Valverde O., Vonesch J.L., Foutz A.S., Boudinot E., et al. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci 1998, 18:7285-7295.
60. Jordan B.A., Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999, 399:697-700.
61. Portoghese P.S., Lunzer M.M. Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord. Eur J Pharmacol 2003, 467:233-234.
62. Wang H.B., Zhao B., Zhong Y.Q., Li K.C., Li Z.Y., Wang Q., et al. Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci USA 2010, 107:13117-13122.
63. Pradhan A.A., Becker J.A., Scherrer G., Tryoen-Toth P., Filliol D., Matifas A., et al. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS One 2009, 4:e5425.